Company: BSX
Filing Date: 2025-02-18
Form Type: 10-K
Source: 0000885725-25-000011
Chunk: 149

Company: BOSTON SCIENTIFIC CORP
Filing Date: 2025-02-18
Form: 10-K
Item: Item 8
Chunk 149
---
 consolidated balance sheets continues to be appropriate.The following represents a roll forward of our goodwill balance by reportable segment:(in millions)MedSurgCardiovascularTotalBalance as of December 31, 2022$4,237 $8,684 $12,920 Goodwill acquired1,110 337 1,447 Impact of foreign currency fluctuations and other changes— 20 20 Balance as of December 31, 2023$5,347 $9,041 $14,387 Goodwill acquired2,172 615 2,787 Impact of foreign currency fluctuations and purchase price and other adjustments(35)(51)(86)Balance as of December 31, 2024$7,483 $9,606 $17,089 In the second quarter of 2024, we performed our annual goodwill impairment test utilizing both the qualitative and quantitative approach described in FASB ASC Topic 350. The qualitative approach was used for testing reporting units where fair value has historically exceeded carrying value by greater than 100 percent, and all other reporting units were tested using the quantitative approach. For the reporting units tested using the quantitative approach, we determined that the fair value of the reporting units exceeded the carrying value and concluded that goodwill was not impaired or at risk of impairment. 

85

Refer to Note A – Significant Accounting Policies for further discussion of our goodwill and intangible asset impairment testing.Estimated Amortization expense for each of the five succeeding fiscal years based upon our amortizable intangible asset portfolio, consisting of intangible assets acquired in a business combination or asset acquisition, as well as internally developed patents, as of December 31, 2024 is as follows:Fiscal Year(in millions)2025$893 2026874 2027835 2028787 2029769 These estimates do not include amortization expense associated with future acquisitions that have been announced but not yet completed as of December 31, 2024.

NOTE D – HEDGING ACTIVITIES AND FAIR VALUE MEASUREMENTS Derivative Instruments and Hedging ActivitiesWe address market risk from changes in foreign currency exchange rates and interest rates through risk management programs which include the use of derivative and nonderivative financial instruments. We operate these programs pursuant to documented corporate risk management policies and do not enter into derivative transactions for speculative purposes. Our derivative instruments do not subject our earnings to material risk, as the gains or losses on these derivatives generally offset losses or gains recognized on